5 stories mentioning HKG:1652Updated 48d ago
Every FINWIRES story that references HKG:1652, newest first.
Fusen Pharmaceutical (HKG:1652) unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology obtained marketing approval for the Peramivir Injection from China's National Medical Products Administration.The drug is for the treatment of influenza A or B virus, according to a Friday Hong Kong bourse filing.
Fusen Pharmaceutical (HKG:1652) said its unit, Henan Fusen Pharmaceutical, agreed to raise 300 million yuan through a capital increase from two state-owned investors, according to a Thursday Hong Kong bourse filing.Nanyang Industrial Investment and Henan Xisheng will subscribe for newly issued equity representing about 34% of Henan Fusen's enlarged registered capital.Following the transaction, Fusen Pharmaceutical's indirect stake in the unit will decrease to about 66%, while the unit will remain a subsidiary.The proceeds will be used mainly to repay debt and replenish working capital.
Fusen Pharmaceutical (HKG:1652) said its wholly owned subsidiary, Jiaheng Pharmaceutical Technology, received marketing approval in China for Piracetam Injection, according to a Hong Kong bourse filing on Tuesday.The product is approved for treating memory impairment and mild to moderate cerebral dysfunction associated with conditions including cerebrovascular diseases, traumatic brain injury, and toxic encephalopathies.
Fusen Pharmaceutical (HKG:1652) unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology obtained marketing approval for Lornoxicam for Injection from China's National Medical Products Administration.The approval is for the indication of the treatment of moderate acute post-operative pain, according to a Monday Hong Kong bourse filing.
Fusen Pharmaceutical (HKG:1652) unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology obtained marketing approval for the Dydrogesterone Tablet from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is for the treatment of diseases and symptoms arising from endogenous progesterone deficiency.
